Stelis is committed to making biological treatments accessible to patients globally.

Our products are targeted against large treatment markets that are currently underserved.


Our hybrid operating model combines differentiated bio-similar, novel biologics and authorized manufacture and marketing of in-licensed biologics. With R&D and cGMP manufacturing out of Bangalore, India we aim to bring world-class treatments at affordable costs to patients in Emerging and Developed countries.
Social Responsibility
Corporate
 
Close
 
    At STELIS our operating principles mirror that of our parent company STRIDES:
  • “Making Decisive Moves That Drive Value” – We foresee emerging trends and successfully execute strategies that deliver on stakeholder expectations.
  • “We Provide a Rewarding and Engaging Work Environment” – We encourage an entrepreneurial work culture that fosters creativity and innovation.
  • “Creating Wealth for Shareholders” – Our pioneering initiatives have delivered consistently for our shareholders
  • “Building Value thru Partnerships” - Our partnership philosophy has helped deliver incremental value to both our company and partners
Close
 
    To fulfill our Mission and Vision, we have a state-of-art R&D and are building a manufacturing infrastructure underpinned by a strong technical foundation to support the three pillars of our business model:
  • Strong partnering activities for in-licensing and out-licensing of products to meet global unmet needs
  • Our Mission is to develop and manufacture affordable bio-therapeutics to address global unmet needs
  • Manufacturing of internal product pipeline & contract development and manufacturing of Drug Substance and Drug Product
Close
 
   

PARTNERING ETHOS

  • Partnering (both technology in-licensing & product out licensing) and Contract Manufacturing activities are identified as crucial to Stelis Biopharma for both risk mitigation by means of adding to internal product pipeline as well for revenue generation.
  • We envision integrated collaborative platform to leverage each organizations’ strengths and to achieve the partnership’s business and strategic objectives. It is imperative that Stelis preserve, protect and enhance relationships with its partners for optimized use of R&D and manufacturing facilities.
  • Other benefits which Stelis could offer potential partners include speed to market, access to cutting edge technology for development and manufacturing of cost competitive products and provide access to newer markets, especially in emerging markets.
  • This partnering philosophy creates shareholder value by bringing potential products to market and generating new revenues and profits for both organizations.
Principles
Business Model
News and Events
Important Information
STATE LEVEL ENVIRONMENT IMPACT ASSESSMENT AUTHORITY (SEIAA), UNDER MOEF, KARNATAKA ACCORDED ENVIRONMENTAL CLEARANCE TO STELIS BIOPHARMA PVT LTD., FOR MANUFACTURE OF BULK BIOLOGICS INCLUDING MONOCLONAL ANTIBODIES AND THERAPEUTIC PROTEINS. COPY OF THE APPROVAL FROM SEIAA 03 IND 2019 DATED 22.08.2019 IS ATTACHED.
stelis.com
©2018. All Rights Reserved.
Connect with
Stelis Pharma
Who We Are
Close
Stelis Biopharma STELIS Biopharma Pvt. Ltd. is a subsidiary of Strides set up in 2013 to consolidate and augment the R&D activities of Inbiopro, which was fully acquired in 2012; and in extending the value chain to manufacturing and commercialisation of the product pipeline.

STELIS is pursuing a blended strategy of-developing both ‘biosimilars’ and ‘novel biotherapeutics’ to a ‘Regulated’ market (US/EU) standard for global markets. Our strategy is to offer high-quality bio-pharmaceuticals at affordable prices initially in high-growth Emerging Markets whose vast patient populations offer un-paralleled opportunities for expanded access.

Vision & Mission
Close
Vision, Mission

Our Vision

To become a globally recognized leader in bio-therapeutics through unsurpassed quality, efficiency and speed

Our Mission

To develop and manufacture affordable bio-therapeutics to address global unmet needs
Our Values
Close
Stelis ValuesAt the core of STELIS values is INTEGRITY. Since STELIS’s core business is to develop life-saving bio-therapeutic drugs, employees are held to the highest standards of ethics and honesty, and are asked to inspire trust in others by saying what they mean, matching their behaviors to their words and taking responsibility for their actions.  STELIS’ core value is supported by its’ value system which include:

Sensitivity

Respects diversity and is responsive to needs of stakeholders (employees, customers, investors & community)

Teamwork

Takes individual and collective responsibility to deliver synergy and excellence in organizational results

Energy

Energizes self and everyone around. Role model in exhibiting passion and perseverance

Leadership

Mobilises organisational resources and leverages capabilities of team to deliver superior results

Integrity

Trust & transparency in thought & behaviour while operating from a system of values

Sustainability

Going beyond compliance to create best practices for long-term value creation
Partnership Philosophy
Close

Partnering (both technology in-licensing & product out licensing) and Contract Manufacturing activities are identified as crucial to Stelis Biopharma for both risk mitigation by means of adding to internal product pipeline as well for revenue generation.

We envision integrated collaborative platform to leverage each organizations’ strengths and to achieve the partnership’s business and strategic objectives. It is imperative that Stelis preserve, protect and enhance relationships with its partners for optimized use of R&D and manufacturing facilities.

Other benefits which Stelis could offer potential partners include speed to market, access to cutting edge technology for development and manufacturing of cost competitive products and provide access to newer markets, especially in emerging markets.

This partnering philosophy creates shareholder value by bringing potential products to market and generating new revenues and profits for both organizations.